Sesen Bio (SESN) Announces Acceptance of Analytical Comparability Plan by FDA to Support BLA of Vicinium for Non-Muscle Invasive Bladder Cancer
Tweet Send to a Friend
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
